166 related articles for article (PubMed ID: 17625458)
1. Use of sargramostim as maintenance therapy in patients with stage IV melanoma at high risk for systemic recurrence.
Hemrajani RH; Kim KB; Amos WR; Mann DE
Melanoma Res; 2007 Aug; 17(4):257-9. PubMed ID: 17625458
[No Abstract] [Full Text] [Related]
2. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ
J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma.
Lutzky J; Weber R; Nunez Y; Gillett M; Spitler L
J Immunother; 2009 Jan; 32(1):79-85. PubMed ID: 19307996
[TBL] [Abstract][Full Text] [Related]
4. The systemic treatment of advanced cutaneous melanoma.
Logan TF
Facial Plast Surg Clin North Am; 2003 Feb; 11(1):75-85. PubMed ID: 15062290
[No Abstract] [Full Text] [Related]
5. Cytokine therapy in advanced melanoma.
Kalaaji AN
J Drugs Dermatol; 2007 Apr; 6(4):374-8. PubMed ID: 17668534
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy for malignant melanoma.
Stoutenburg JP; Schrope B; Kaufman HL
Expert Rev Anticancer Ther; 2004 Oct; 4(5):823-35. PubMed ID: 15485316
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.
Daud AI; Mirza N; Lenox B; Andrews S; Urbas P; Gao GX; Lee JH; Sondak VK; Riker AI; Deconti RC; Gabrilovich D
J Clin Oncol; 2008 Jul; 26(19):3235-41. PubMed ID: 18591558
[TBL] [Abstract][Full Text] [Related]
8. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
[TBL] [Abstract][Full Text] [Related]
9. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
[TBL] [Abstract][Full Text] [Related]
10. Randomized trials in melanoma: an update.
Eggermont AM
Surg Oncol Clin N Am; 2006 Apr; 15(2):439-51. PubMed ID: 16632225
[TBL] [Abstract][Full Text] [Related]
11. Management of metastatic melanoma 2005.
O'Day S; Boasberg P
Surg Oncol Clin N Am; 2006 Apr; 15(2):419-37. PubMed ID: 16632224
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant interferon therapy for melanoma.
Hancock B; Wheatley K; Ives N; Gore M
J Clin Oncol; 2005 Apr; 23(10):2431; author reply 2431-2. PubMed ID: 15800339
[No Abstract] [Full Text] [Related]
13. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
Kirkwood JM; Tarhini AA
J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
[No Abstract] [Full Text] [Related]
14. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
15. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.
Glaspy J; Atkins MB; Richards JM; Agarwala SS; O'Day S; Knight RD; Jungnelius JU; Bedikian AY
Cancer; 2009 Nov; 115(22):5228-36. PubMed ID: 19728370
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell immunotherapy for stage IV melanoma.
O'Rourke MG; Johnson MK; Lanagan CM; See JL; O'Connor LE; Slater GJ; Thomas D; Lopez JA; Martinez NR; Ellem KA; Schmidt CW
Melanoma Res; 2007 Oct; 17(5):316-22. PubMed ID: 17885587
[TBL] [Abstract][Full Text] [Related]
17. Dual fronts poised to transform melanoma therapy.
Mullard A
Nat Rev Drug Discov; 2011 May; 10(5):325-6. PubMed ID: 21532549
[No Abstract] [Full Text] [Related]
18. [Working group of Dermatologic Oncology ADO. Second-line therapy in stage IV melanoma].
J Dtsch Dermatol Ges; 2007 Oct; 5(10):959. PubMed ID: 17910683
[No Abstract] [Full Text] [Related]
19. Malignant melanoma: a case report.
Arena PJ
J Ky Med Assoc; 1973 Feb; 71(2):84-6. PubMed ID: 4687467
[No Abstract] [Full Text] [Related]
20. Long-term remissions in metastatic malignant melanoma following chemotherapy and tamoxifen maintenance.
Metzner B; Casper J; Hartung G; Rosien B; Hölzle E; Pelzer P; Köhne CH
Onkologie; 2011; 34(4):208-9. PubMed ID: 21447982
[No Abstract] [Full Text] [Related]
[Next] [New Search]
